Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Carrington Laboratories has announced that its wholly-owned subsidiary, DelSite Biotechnologies, has entered into a non-exclusive technology evaluation agreement with a global pharmaceutical company for evaluating DelSite's GelSite polymer-based delivery technologies.
Subscribe to our email newsletter
The goal of the program is to evaluate DelSite’s parenteral technologies. DelSite has also agreed to provide GelSite polymer and technical information concerning the optimal solubilization and mixing conditions.
GelSite polymer is a novel, naturally-occurring ionic carbohydrate polymer that is capable of forming a gel upon contact with body fluids. DelSite has also completed a series of toxicology studies on GelSite polymer and the delivery platforms.
Carlton Turner, president and CEO of Carrington Laboratories and DelSite Biotechnologies, said: “DelSite’s technologies are novel and patent-protected, and we are dedicated to developing them for a wide range of applications. This agreement represents another highlight of increased interest in DelSite’s technologies within the pharmaceutical industry.”